During the fourth quarter, the Harbor Health Care ETF returned –10.89%, underperforming the Russell 3000 Growth Health Care ...

We recently published a list of 10 Stocks Under $10 that Will Triple. In this article, we are going to take a look at where ...

SC decision comes as a huge relief for Mamata Banerjee and her entire cabinet battered with the dismissal of 25,753 teaching ...

Not only are biotech stocks subject to the boom-or-bust nature of their therapeutics, but they also operate in a cyclical ...

Sapirstein had only held the title for 32 days, assuming the executive chairman role after the company’s latest CEO resigned ...

Apollomics has tagged out of its partnership with TYG Oncology, terminating an immuno-oncology pact as part of a push to cut ...

The group had a bad week after turmoil at the FDA, continuing a long period of underperformance following the pandemic.

Learn more about whether Alvotech or Legend Biotech Corporation is a better investment based on AAII's A+ Investor grades, which compare both companies' key financial metrics.

Sangamo Therapeutics has stacked up $18 million cash from Eli Lilly in a licensing deal that will let the pharma use the ...

I-Mab (NASDAQ: IMAB) is a U.S.-based, global biotech company, focused on the development of precision immuno-oncology agents for the treatment of cancer. I-Mab has established operations in the U.S.

Analysts at Precedence Research expect the gene-editing market to grow 15.7% annually and reach $40.1 billion by 2034, ...

BioPharma Credit (LSE: BPCR) is one of the more esoteric investment trusts listed in London. Biotech is a specialist sector ...